Utility of Whole Genome Sequencing in Fetuses With Abnormal Ultrasound Findings
20 maja 2026 zaktualizowane przez: Women's Hospital School Of Medicine Zhejiang University
Clinical Study on Prenatal Diagnosis of Fetal Abnormalities of Unknown Cause Using Whole-Genome Sequencing: A Multicenter Study
The goal of this observational study is to learn if whole-genome sequencing (WGS) can help find the genetic cause in fetuses with structural abnormalities that remain unexplained after standard genetic testing (such as karyotyping, chromosomal microarray, or whole-exome sequencing). It will also learn how WGS results may affect pregnancy management and family decision-making.
The main questions it aims to answer are:
How often does WGS identify a genetic cause in these fetuses? Does WGS find more genetic causes compared to standard genetic tests? Can combining WGS with other molecular analyses help discover new disease genes or pathways? Researchers will compare WGS results to results from standard genetic tests to see if WGS finds more genetic causes.
Participants are pregnant women whose fetuses have structural abnormalities seen on ultrasound or MRI, with negative results from routine genetic testing. Participants will:
Undergo an invasive procedure (such as amniocentesis) or provide postnatal samples as part of their regular medical care Allow the use of leftover samples for WGS and additional molecular studies Be followed until after delivery to collect information on pregnancy outcomes and neonatal health
Przegląd badań
Status
Rekrutacyjny
Warunki
Typ studiów
Obserwacyjny
Zapisy (Szacowany)
1000
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Kontakt w sprawie studiów
- Nazwa: Qiong Luo
- Numer telefonu: +86 571 89998819
- E-mail: luoq@zju.edu.cn
Lokalizacje studiów
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chiny, 310006
- Rekrutacyjny
- Women's Hospital School of Medicine Zhejiang University
-
Kontakt:
- Qiong Luo
- Numer telefonu: +86 571 89998819
- E-mail: luoq@zju.edu.cn
-
Huzhou, Zhejiang, Chiny, 313000
- Rekrutacyjny
- Huzhou Maternity & Child Care Hospital
-
Kontakt:
- Liping Qiu
- Numer telefonu: +86 15906823270
- E-mail: 392686340@qq.com
-
Quzhou, Zhejiang, Chiny, 324000
- Rekrutacyjny
- Quzhou Maternal and Child Health Care Hospital
-
Kontakt:
- Yuying Zhu
- Numer telefonu: +86 15257023995
- E-mail: zhuyuy123@163.com
-
Shaoxing, Zhejiang, Chiny, 312000
- Rekrutacyjny
- Shaoxing Maternity & Child Care Hospital
-
Kontakt:
- Hualin Xu
- Numer telefonu: +86 13867526767
- E-mail: xhl0175@sina.cn
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Nie
Metoda próbkowania
Próbka bez prawdopodobieństwa
Badana populacja
Pregnant women aged 18 years or older with singleton pregnancies, whose fetuses have structural abnormalities detected by ultrasound or MRI between 11+0 and 32+0 weeks of gestation, and who are scheduled to undergo invasive or postnatal genetic diagnostic procedures.
Opis
Inclusion Criteria:
- Pregnant women aged ≥ 18 years.
- Singleton pregnancy.
- Gestational age between 11+0 and 32+0 weeks, with ultrasound or MRI indicating a definite structural malformation in the fetus (may be with or without soft marker abnormalities) requiring prenatal diagnosis (see Appendices 1 and 2). Fetal developmental abnormalities include those of the central nervous system, cardiovascular system, craniofacial/neck region, chest/mediastinum, abdomen/digestive tract, urinary system, skeletal system/limbs, and systemic abnormalities such as fetal hydrops, abnormally thickened placenta with hydrops, and severe growth restriction. Criteria for ultrasound soft markers and structural malformations are provided in the appendices.
- Planned to undergo at least one invasive or postnatal procedure for genetic diagnosis, and consent to the use of residual diagnostic samples for research testing.
- Signed unified informed consent form, agreement to follow-up, and consent for storage and submission of samples and data according to the protocol.
Exclusion Criteria:
- Age < 18 years or individuals lacking full capacity for civil conduct.
- Twin or multiple pregnancies.
- Known parental or familial carrier status of a pathogenic variant highly consistent with the current fetal phenotype, where testing is planned only for targeted confirmation.
- Refusal to consent to the storage and use of samples and data for this study.
- Other conditions deemed unsuitable for participation in this study by the investigator.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Diagnostic yield of WGS
Ramy czasowe: 8 weeks after enrollment of the last participant
|
Proportion of fetuses with structural malformations or significant ultrasound abnormalities in whom whole-genome sequencing (WGS) using fetal and related tissues identifies at least one pathogenic or likely pathogenic variant.
Overall diagnostic yield (including pathogenic/likely pathogenic variants and variants of uncertain significance reclassified as pathogenic/likely pathogenic based on additional evidence) will also be reported.
|
8 weeks after enrollment of the last participant
|
|
Comparison of diagnostic increment of WGS vs. standard clinical testing pathway
Ramy czasowe: 12 weeks after enrollment of the last participant
|
Difference in diagnostic rate (proportion of fetuses with pathogenic/likely pathogenic variants) between whole-genome sequencing (WGS) and the current standard clinical testing pathway (karyotyping, CMA/CNV-seq, WES/panel).
Stratified analysis by malformation type (e.g., isolated CNS, cardiac, skeletal, multiple systems) and by pattern of system involvement will be reported.
|
12 weeks after enrollment of the last participant
|
|
Number of novel candidate disease genes and enriched molecular pathways
Ramy czasowe: At study completion (average 24 months after first participant enrollment)
|
Count of novel candidate disease genes or regulatory elements identified by integrated multi-omics analysis.
List of enriched KEGG pathways and GO terms (with FDR < 0.05) associated with fetal developmental abnormalities.
|
At study completion (average 24 months after first participant enrollment)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Phenotypic stratification system and gene pathway enrichment results
Ramy czasowe: At study completion (average 24 months after first participant enrollment)
|
Phenotypic classification system (based on organ/system involvement: isolated, multiple, syndromic).
For each subtype: (1) count and frequency of pathogenic/likely pathogenic variants; (2) count of variant types (SNV, Indel, SV, CNV); (3) list of enriched KEGG pathways and GO terms with FDR < 0.05.
|
At study completion (average 24 months after first participant enrollment)
|
|
Reclassification rate of variants of uncertain significance (VUS) and impact on counseling decisions
Ramy czasowe: At study completion (average 24 months after first participant enrollment)
|
Proportion of VUS reclassified to pathogenic/likely pathogenic or benign/likely benign after multi-omics integration.
Number of participants/families with altered genetic counseling or clinical decision-making (e.g., termination, prenatal intervention, postnatal follow-up plan) due to reclassification.
|
At study completion (average 24 months after first participant enrollment)
|
|
Establishment of a multicenter database and biobank
Ramy czasowe: At study completion (average 24 months after first participant enrollment)
|
A unified, relational database containing de-identified clinical phenotypes, genotypes (WGS variants), multi-omics data (e.g., transcriptomic, epigenomic), and biospecimen inventory (e.g., DNA, RNA, plasma, tissue blocks) from participating centers.
Database completion will be defined as ≥90% of expected participants with all required data types uploaded and quality-controlled.
Biobank completion will be defined as ≥90% of expected biospecimens collected, processed, and stored with traceable metadata.
|
At study completion (average 24 months after first participant enrollment)
|
|
Standardized data submission and sharing protocols
Ramy czasowe: At study completion (average 24 months after first participant enrollment)
|
Completion of a written protocol document (yes/no) covering sample submission, data formats, quality thresholds, reporting template (ACMG/AMP classification), clinical data dictionary, and de-identification rules, with sign-off obtained from all participating centers' principal investigators and data managers.
|
At study completion (average 24 months after first participant enrollment)
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
12 marca 2026
Zakończenie podstawowe (Szacowany)
12 września 2027
Ukończenie studiów (Szacowany)
12 marca 2028
Daty rejestracji na studia
Pierwszy przesłany
9 kwietnia 2026
Pierwszy przesłany, który spełnia kryteria kontroli jakości
20 maja 2026
Pierwszy wysłany (Rzeczywisty)
26 maja 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
26 maja 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
20 maja 2026
Ostatnia weryfikacja
1 marca 2026
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- IRB-20260095-R
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .